Colorcon
VC Fund
Harleysville, United States
Colorcon is a company that specializes in the design and development of specialty excipients for solid oral dosages for the pharmaceutical and nutritional industries.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Colorcon invests in
Stages Colorcon invests in
Countries Colorcon invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kelly Boyer
|
|||
Simon Tasker
|
|||
3 more contacts available
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Nutrition 1 (50%)
- Life Science 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kelly Boyer
Executive
|
Executive | Total investments: 3 | Find email | |
|
Simon Tasker
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MEND
|
MEND is a life sciences company with a mission to help people heal and live their healthiest. The company is currently researching and developing targeted clinical nutrition and medical food interventions to enhance patient outcomes, from injury and surgery to aging and physical performance. MEND has been adopted by numerous hospitals, healthsystems, professional sports teams across all major leagues, and the elite forces of the US Military. The company is headquartered in New York City. | $16.5M / Series A / Jun 06, 2023 | |
Numerion Labs
|
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any otherAI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com, or connect on Twitter and LinkedIn. | $123M / Series B / Aug 11, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Colorcon invest in?
Colorcon invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Colorcon?
Public channels for Colorcon include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Colorcon?
The team at Colorcon includes Kelly Boyer (Executive) and Simon Tasker (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
